Navigation Links
MDS researchers join forces to advance patient treatments and outcomes
Date:6/18/2012

NEW YORK (June 18, 2012) NewYork-Presbyterian/Weill Cornell Medical Center is one of six institutions selected to join the newly-founded MDS Clinical Research Consortium. The Consortium's mission is to significantly advance treatments and patient outcomes for Myelodysplastic Syndromes (MDS) through innovative research and clinical trials.

The five-year, $16 million multi-institution initiative is the first privately funded MDS research consortium in the United States. It is sponsored by the Aplastic Anemia & MDS International Foundation of Rockville, Md., and supported by the Edward P. Evans Foundation. The Consortium's funding to Weill Cornell Medical College will support MDS research at NewYork-Presbyterian/Weill Cornell Medical Center.

MDS is a cancer of bone marrow stem cells that inhibits the body's ability to produce healthy blood cells. The disease can be treated and, in some cases, controlled, but currently, the only cure is stem cell transplantation. The new Consortium will help fill a major gap in the United States for MDS-related clinical research by joining dedicated academic medical centers with a high volume of MDS patients, an established database of current and former patients and a significant track record of participation in MDS clinical trials. The collaboration will facilitate evaluation of promising new compounds, epidemiological studies and translational research studies leading to new classifications, treatments and procedures for MDS.

"MDS is an under-recognized disease. Sometimes we don't know why a patient has developed MDS, but we do know that those who have been exposed to cancer chemotherapy and radiation therapy are at increased risk," says Dr. Gail J. Roboz, Weill Cornell Medical College's principal investigator for the Consortium and director of the Leukemia Program at NewYork-Presbyterian/Weill Cornell Medical Center. "This Consortium offers a wonderful opportunity to develop new therapies and also to profile patients using the latest, state-of-the-art technologies so we can start to understand who gets MDS and why."

Other Consortium partners include the Cleveland Clinic's Taussig Cancer Institute, Dana-Farber Cancer Institute, MD Anderson Cancer Center, H. Lee Moffitt Cancer Center and Research Institute and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

"One of the greatest challenges in research of rare diseases like MDS is having enough patients to conduct meaningful clinical trials. No single center can do it alone. This uniquely collaborative effort overcomes that barrier," said John Huber, Executive Director of the Aplastic Anemia & MDS International Foundation. "To have these six leading MDS research centers working together in this way is unprecedented," Huber added. The Aplastic Anemia & MDS International Foundation will expand its programs for MDS patients, their families, and caregivers and local physicians who support and complement the aims and purposes of the Consortium.

"We are extremely pleased to work in partnership with AA&MDSIF and these six outstanding Consortium members. This collaborative endeavor reflects Mr. Evans' desire to support the highest quality MDS research, which will lead to improved treatments for patients and, ultimately, to finding a cure," said an Evans Foundation trustee.


'/>"/>

Contact: Lauren Woods
law2014@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Related medicine news :

1. Stanford researchers discover the African cichlids noisy courtship ritual
2. Researchers determine pathway for origin of most common form of brain and spinal cord tumor
3. UCI researchers create mosquitoes incapable of transmitting malaria
4. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
5. Penn and Cornell researchers spearhead the development of new guidelines for veterinary CPR
6. VCU researchers identify changes in cholesterol metabolic pathways
7. An important breakthrough in immunology by IRCM researchers
8. Mount Sinai researchers develop a multi-target approach to treating tumors
9. Doubling down on heart failure: Researchers discover new route to disease, and drugs to match
10. Researchers at IRB Barcelona uncover new clues about the origin of cancer
11. HIV drug may slow down metastatic breast cancer, say researchers at Jeffersons Kimmel Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2020)... ... ... The Northern Virginia Community College Educational Foundation (NOVA Foundation) is proud to announce ... Florida. Ms. Howe is adding to her existing endowed scholarship fund to increase ... ever given the current pandemic. Ms. Howe has also generously donated to the NOVA ...
(Date:4/1/2020)... ... April 02, 2020 , ... Medical Device Change Management, An FDAnews ... , What change management method should one be using for a medical ... on the type of change. Is it due to post-market design change, production process ...
(Date:4/1/2020)... ... April 01, 2020 , ... Global mobile data platform provider Zerion ... adjusting to new needs based on COVID-19. , As cases continue to rise across ... types. , Zerion will extend support by offering free basic iFormBuilder accounts and forms ...
(Date:3/28/2020)... HOLMDEL, N.J. (PRWEB) , ... March 27, 2020 ... ... UAV services division of the Suntuity Group of companies, is mobilizing their drone ... the COVID-19 coronavirus. , By leveraging their DJI Enterprise level Matrice and Agras ...
(Date:3/28/2020)... ... March 27, 2020 , ... Ahead of National ... edition of “The Fertility Journey.” This campaign will serve as a guide, showcasing ... maternal health options. , One in 6 couples experiences trouble with fertility. ...
Breaking Medicine News(10 mins):
(Date:3/30/2020)... ... March 30, 2020 , ... ... is now offering 'Ask A Technician' service. , "We are very excited to ... added, "A certified technician at the Institute of Tattoo Removal is available to ...
(Date:3/28/2020)... , ... March 27, 2020 , ... ... Isagenix International has named Gary Gallant as its permanent CIO. In this ... company’s technology vision, ensuring Isagenix can provide a smooth shopping experience for customers ...
(Date:3/27/2020)... ... March 27, 2020 , ... A new survey conducted ... holistic portfolios, revealed that college-bound young adults are reconsidering their higher education options ... barriers to high school senior’s path to college and possibly dashing those hopes ...
Breaking Medicine Technology: